Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Turn Therapeutics Inc. (TTRX)

Turn Therapeutics to present atopic dermatitis data at Stifel forum on September 23, 2026

Neutral Impact 1 of 5 other Written later

Turn Therapeutics announced that its CEO Bradley Burnam and Executive Clinical and Regulatory Lead Stephen M. Hahn, M.D., will present at the Stifel 2026 Virtual Immunology and Inflammation Forum. The presentation covers the atopic dermatitis clinical program, including a pruritus-focused stage 2 enrichment strategy. The filing is a routine investor event notice and contains no financial results or guidance.

Key points

  • Presentation scheduled for September 23, 2026 at 1:30 PM ET
  • Presenters: Bradley Burnam, CEO, and Stephen M. Hahn, M.D., Executive Clinical and Regulatory Lead
  • Topics include the stage 2 enrichment strategy and patient populations with moderate-severe baseline pruritus and lower EASI scores
  • Live webcast and replay available on the Turn Therapeutics investor website

The filing

CompanyTurn Therapeutics Inc. (TTRX)
Form8-K, current report
Filed with the SECSep 10, 2026, 8:10 AM ET
Accession number0001213900-26-098584

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 10, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.